Comment from AbbVie

Summary: AbbVie, a biopharmaceutical company, supports the FDA's efforts to develop guidance on the use of AI in regulatory decision-making for drug and biological products. They provide specific recommendations to improve the draft guidance, including adopting harmonized AI definitions, incorporating Good Machine Learning Practice (GMLP) principles, and providing more detailed examples and templates for the risk-based credibility assessment framework.